IN INTEGRATIVE OMICS APPROACH IN HUMAN DISEASE RESEARCH
EAS Academy. Suhre K. 06/01/16; 136732 Topic: Lipids lipoproteins and metabolism
Prof. Karsten Suhre
Prof. Karsten Suhre

Access to Premium Content is a benefit of Individual EAS membership. Apply for membership


Access EAS content "anytime, anywhere" with the EAS Academy App for iOS and Android


For any questions contact us at office@eas-society.org

Learning Objectives
Abstract
References
Discussion Forum (0)
Rate & Comment (0)
Attendants shall learn about metabolomics as a biomedical research tool, genetic variation in human metabolism, and the concept of human metabolic individuality.
Evidence from genome-wide association studies indicates that common genetic variants influence the metabolic composition of the individual, and hence their susceptibility to complex diseases such as cardiovascular disease and type 2 diabetes. However, information on the underlying biological processes is often lacking. To unravel the complex mechanisms underlying these molecular processes and to understand how the different functional levels interact with each other, new approaches are required to allow for interrogation of molecular alterations in human disease, hence the development of an integrative 'omics' approach.

Analysis of ​genotype-dependent metabolic phenotype is one example of an 'omics' approach which can provide information on the susceptibility to metabolic traits, thereby allowing clinicians the possibility of tailoring treatment to the individual. Studies to date have identified over 150 genetic loci associated with blood metabolite concentrations, which have provided functional insights relevant for cardiovascular disease. Indeed, most individuals carry one or more risk alleles that may influence susceptibility to disease, response to a specific pharmacotherapy, or dietary or environmental factors.

The 'omics' approach to human disease research is increasingly important in the context of personalized medicine, where treatment decisions are based on patients' omics, demographic, clinical and environmental data, and also offers opportunities for targeted pharmacotherapeutic development.
Evidence from genome-wide association studies indicates that common genetic variants influence the metabolic composition of the individual, and hence their susceptibility to complex diseases such as cardiovascular disease and type 2 diabetes. However, information on the underlying biological processes is often lacking. To unravel the complex mechanisms underlying these molecular processes and to understand how the different functional levels interact with each other, new approaches are required to allow for interrogation of molecular alterations in human disease, hence the development of an integrative 'omics' approach.

Analysis of ​genotype-dependent metabolic phenotype is one example of an 'omics' approach which can provide information on the susceptibility to metabolic traits, thereby allowing clinicians the possibility of tailoring treatment to the individual. Studies to date have identified over 150 genetic loci associated with blood metabolite concentrations, which have provided functional insights relevant for cardiovascular disease. Indeed, most individuals carry one or more risk alleles that may influence susceptibility to disease, response to a specific pharmacotherapy, or dietary or environmental factors.

The 'omics' approach to human disease research is increasingly important in the context of personalized medicine, where treatment decisions are based on patients' omics, demographic, clinical and environmental data, and also offers opportunities for targeted pharmacotherapeutic development.
v Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, Walter K, Menni C, Chen L, Vasquez L, Valdes AM, Hyde CL, Wang V, Ziemek D, Roberts P, Xi L, Grundberg E, The MuTHER Consortium, Waldenberger M, Richards JB, Mohney RP, Milburn MV, John SL, Trimmer J, Theis FJ, Overington JP, Suhre K, Brosnan MJ, Gieger C, Kastenmüller G, Spector TD, Soranzo N. An atlas of genetic influences on human blood metabolites. Nature Genetics 2014;46:543-50.

Petersen AK, Zeilinger S, Kastenmüller G, Römisch-Margl W, Brugger M, Peters A, Meisinger C, Strauch K, Hengstenberg C, Pagel P, Huber F, Mohney RP, Grallert H, Illig T, Adamski J, Waldenberger M, Gieger C, Suhre K. Epigenetics meets metabolomics: An epigenome-wide association study with blood serum metabolic traits. Hum Mol Genet 2014;23:534-45.

Altmaier E, Fobo G, Heier M, Thorand B, Meisinger C, Römisch-Margl W, Waldenberger M, Gieger C, Illig T, Adamski J, Suhre K, Kastenmüller G. Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism. Eur J Epidemiol 2014;29:325-36.​
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies